---

$0.97

+0.0004 ( +0.04% ) N/A

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-05-21	Buy	1388794.00	Lynx1 Capital Management LP
2024-12-16	Buy	31800.00	Lynx1 Capital Management LP
2024-11-19	Buy	947.00	Lynx1 Capital Management LP
2024-09-24	Buy	5000.00	Klencke Barbara
2024-08-27	Buy	5000.00	Klencke Barbara
2024-06-14	Sale	-47500.00	Woods Keith
2024-06-14	Sale	-47500.00	Dorton Katina
2024-06-14	Sale	-47500.00	BAKER BROS. ADVISORS LP
2024-06-14	Sale	-47500.00	Nicholson Garry A
2024-06-14	Sale	-47500.00	Gruia Gabriela